REPL
NASDAQ · Biotechnology
Replimune Group Inc
$6.98
+0.09 (+1.31%)
Financial Highlights (FY 2025)
Revenue
90.24M
Net Income
-25,675,790
Gross Margin
42.1%
Profit Margin
-28.5%
Rev Growth
-3.7%
D/E Ratio
1.03
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 42.1% | 42.1% | 42.1% |
| Operating Margin | -24.2% | -20.7% | -23.4% |
| Profit Margin | -28.5% | -29.9% | -25.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.24M | 87.45M | 85.26M |
| Gross Profit | 38.03M | 36.86M | 35.93M |
| Operating Income | -21,880,088 | -18,118,926 | -19,916,222 |
| Net Income | -25,675,790 | -26,182,971 | -21,946,443 |
| Gross Margin | 42.1% | 42.1% | 42.1% |
| Operating Margin | -24.2% | -20.7% | -23.4% |
| Profit Margin | -28.5% | -29.9% | -25.7% |
| Rev Growth | -3.7% | +3.8% | +9.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 349.99M | 286.09M | 339.78M |
| Total Equity | 338.62M | 342.02M | 366.57M |
| D/E Ratio | 1.03 | 0.84 | 0.93 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -28,181,466 | -22,488,865 | -22,555,214 |
| Free Cash Flow | -17,519,035 | -21,453,021 | -16,827,154 |